e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
Multidrug-resistant and extensively drug-resistant tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Poor infection control increase risk of reinfection with MDR or XDR-TB strains
V. Crudu, S. Ruch-Gerdes, S. Niemann, N. Moraru, L. Carchilan, V. Lesan, G. Blagodeteleva, E. Stratan (Chisinau, Republic Of Moldova; Borstel, Germany)
Source:
Annual Congress 2010 - Multidrug-resistant and extensively drug-resistant tuberculosis
Session:
Multidrug-resistant and extensively drug-resistant tuberculosis
Session type:
Oral Presentation
Number:
350
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Crudu, S. Ruch-Gerdes, S. Niemann, N. Moraru, L. Carchilan, V. Lesan, G. Blagodeteleva, E. Stratan (Chisinau, Republic Of Moldova; Borstel, Germany). Poor infection control increase risk of reinfection with MDR or XDR-TB strains. Eur Respir J 2010; 36: Suppl. 54, 350
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Evaluation of the multidrug resistant TB in children with HIV infection
Source: Eur Respir J 2004; 24: Suppl. 48, 439s
Year: 2004
Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
Source: Eur Respir J, 55 (6) 1902383; 10.1183/13993003.02383-2019
Year: 2020
Bedaquiline in treatment of TB/HIV co-infection patients with extremely-drug resistance of MBT
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018
Treatment outcomes for multidrug-resistant tuberculosis (MDR-TB) patients in Africa
Source: Annual Congress 2011 - Multidrug-resistant tuberculosis
Year: 2011
Extensively drug-resistant tuberculosis (XDR-TB) treatment outcome. Cohort study
Source: Annual Congress 2010 - Multidrug-resistant and extensively drug-resistant tuberculosis
Year: 2010
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
Source: Eur Respir J 2013; 41: 1393-1400
Year: 2013
Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance
Source: Eur Respir J, 50 (1) 1700598; 10.1183/13993003.00598-2017
Year: 2017
Multidrug-resistant TB in children with HIV infection
Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases
Year: 2007
Extensively drug resistant tuberculosis (XDR TB) in a high income country: a report of four unrelated cases
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007
Prevalence of MDR and XDR tuberculosis among patients with failure of re-treatment course
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008
Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007
Tuberculosis in household contacts of multidrug-resistant tuberculosis patients
Source: Annual Congress 2011 - Multidrug-resistant tuberculosis
Year: 2011
Treatment outcomes of extensively-drug resistant tuberculosis (XDR-TB) patients in 20 countries
Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Year: 2012
Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
A multicentric cohort analysis of culture conversion and reversion in multidrug resistant tuberculosis (MDRTB) patients
Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights
Year: 2013
Multidrug resistant tuberculosis (MDR – TB) treatment outcomes in Iran
Source: Eur Respir J 2004; 24: Suppl. 48, 657s
Year: 2004
Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB
Source: Eur Respir J 2009; 33: 1085-1094
Year: 2009
Increasing incidence of fluoroquinolone resistant tuberculosis in Bombay
Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis
Year: 2005
Analysis of antibiotic resistance and enterococcal infections of low respiratory infection on patients in hospital
Source: Eur Respir J 2003; 22: Suppl. 45, 450s
Year: 2003
Are multi-drug resistant (MDR) pathogens related to higher mortality in pneumonia?
Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept